Hologic, Inc. (HOLX) Receives $45.25 Consensus Price Target from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have been given an average recommendation of “Buy” by the fourteen ratings firms that are covering the stock. Four equities research analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $46.92.

A number of analysts recently commented on HOLX shares. Piper Jaffray Companies upgraded shares of Hologic from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $44.00 to $48.00 in a research note on Wednesday, January 4th. Evercore ISI cut shares of Hologic from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research note on Wednesday, January 4th. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research note on Friday, January 6th. Jefferies Group LLC restated a “buy” rating and set a $46.00 price objective on shares of Hologic in a research note on Sunday, January 8th. Finally, Deutsche Bank AG restated a “buy” rating and set a $48.00 price objective on shares of Hologic in a research note on Wednesday, January 18th.

Shares of Hologic (NASDAQ:HOLX) traded up 0.09% during mid-day trading on Monday, reaching $43.30. 2,495,476 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $42.33 and a 200-day moving average price of $39.95. Hologic has a one year low of $32.64 and a one year high of $43.31. The stock has a market cap of $12.09 billion, a PE ratio of 37.01 and a beta of 1.10.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 1st. The medical equipment provider reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.01. The company earned $734.40 million during the quarter, compared to analysts’ expectations of $725.01 million. Hologic had a net margin of 11.57% and a return on equity of 27.17%. Hologic’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the business earned $0.46 EPS. On average, analysts predict that Hologic will post $1.98 EPS for the current year.

In other news, Director Sally Crawford sold 17,396 shares of the business’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $42.00, for a total transaction of $730,632.00. Following the transaction, the director now owns 152,305 shares of the company’s stock, valued at approximately $6,396,810. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Elaine Ullian sold 9,423 shares of the business’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $39.54, for a total transaction of $372,585.42. Following the transaction, the director now directly owns 36,798 shares in the company, valued at approximately $1,454,992.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,680 shares of company stock worth $1,945,862. 0.79% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Global X Management Co. LLC boosted its position in shares of Hologic by 149.9% in the third quarter. Global X Management Co. LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 2,322 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Hologic by 159.1% in the third quarter. Tower Research Capital LLC TRC now owns 4,465 shares of the medical equipment provider’s stock worth $173,000 after buying an additional 2,742 shares during the last quarter. Cornercap Investment Counsel Inc. bought a new position in Hologic during the fourth quarter worth approximately $202,000. Commerzbank Aktiengesellschaft FI bought a new position in Hologic during the fourth quarter worth approximately $207,000. Finally, Boston Advisors LLC bought a new position in Hologic during the third quarter worth approximately $202,000. 94.09% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/04/21/hologic-inc-holx-given-average-rating-of-buy-by-brokerages-updated-updated.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit